https://bioutah.org/u-s-fda-accepts-tevas-new-drug-application-nda-and-grants-priority-review-for-ecopipam-for-pediatric-patients-with-tourette-syndrome/2026-08-20T21:16:45ZBioUtahenU.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome2026-08-20T21:16:45ZBloghttps://bioutah.org/sera-prognostics-appoints-scott-gleason-cfo/2026-08-20T21:14:38ZBioUtahenSera Prognostics Appoints Scott Gleason CFO2026-08-20T21:14:38ZBloghttps://bioutah.org/merit-medical-announces-global-operations-leadership-transition/2026-08-20T21:12:52ZBioUtahenMerit Medical Announces Global Operations Leadership Transition2026-08-20T21:12:52ZBloghttps://bioutah.org/utah-life-sciences-innovation-caucus-ulsic-breakfast/2026-08-20T22:16:58ZBioUtahenUtah Life Sciences Innovation Caucus Breakfast2026-08-20T21:10:06ZBloghttps://bioutah.org/curavit-expands-clinical-research-capabilities-with-acquisition-of-lindus-health-cro-assets-accelerating-global-trial-execution-for-life-science-sponsors/2026-08-20T21:08:36ZBioUtahenCuravit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors2026-08-20T21:08:12ZBlog